ABSTRACT
INTRODUCTION
Tremendous advances in the treatment and understanding of the pathophysiology of retinopathy of prematurity (ROP) have resulted from multiple, welldesigned clinical trials including Cryotherapy for Retinopathy of Prematurity (CRYO-ROP), 1 Early Treatment for Retinopathy of Prematurity (ETROP), 2, 3 and others. More recently, with the increased availability of pharmacotherapeutics actively against vascular endothelial growth factor (VEGF), there is a growing interest in anti-VEGF treatment for ROP (Figure 1) . 4 ROP exhibits a hypoxia-induced rise in VEGF levels resulting in abnormal vessel growth [5] [6] [7] [8] [9] and anti-VEGF therapies are ideally suited to target the phase of ROP during which VEGF is upregulated. Studies have shown increased vitreous VEGF levels in ROP, especially with clinically evident vascular activity, 10 and intravitreal anti-VEGF injections have been shown to decrease intraocular VEGF levels. 11 Despite the prospective, multicenter randomized control trial (Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity [BEAT-ROP]) 12 examining the efficacy of primary intravitreal anti-VEGF (bevacizumab) versus laser therapy for zone I, stage 3 with plus disease or posterior zone II, stage 3 with plus disease, controversy persists surrounding the ideal treatment for ROP. 4 A systematic analysis 13 and an evidence-based meta-analysis 14 of VEGF inhibition as a treatment for ROP have been published but are not exhaustive in their scope.
We performed an up-to-date and comprehensive literature search of PubMed (terms: "retinopathy of prematurity", "ROP," "anti-VEGF," "Avastin®", "bevacizumab," "Lucentis®," "ranibizumab," "Macugen®", "pegaptanib," "Eylea®", and "aflibercept") with the objective of presenting the published studies on this growing treatment modality for ROP. Since 2006, there have been more than 55 clinical studies (Table A, available in the online version of this article) on the use of VEGF therapies for ROP with an increasing number of reports in recent years (Figure 1 ).
However, laser therapy also has established advantages. The ETROP study demonstrated that treatment is effective at type 1 prethreshold disease. 2, 3 There is also significant experience with the potential local and systemic adverse events associated with laser photocoagulation for ROP (eg, although potentially more stressful for the neonate given longer treatment times compared to intravitreal anti-VEGF therapy, there are no systemic adverse events specifically related to laser therapy). In addition, the rate of recurrence and time to recurrence of ROP may be more predictable with laser treatment. Some studies have advocated for combination treatment of intravitreal anti-VEGF and laser treatment. 19 Regardless, it has not yet been determined whether intravitreal anti-VEGF monotherapy, laser photocoagulation monotherapy, or a combination of both is the best therapy for treatment-requiring ROP.
INTRAVITREAL ANTI-VEGF AGENTS USED
TO TREAT ROP Studies most commonly report on the use of bevacizumab (Avastin; Genentech, South San Francisco, CA) for the treatment of ROP; however, there is renewed interest in the use of pegaptanib (Macugen; Bausch & Lomb, Rochester, NY) 20, 21 given its selective suppression of VEGF-165, and a limited number of reports on the use of ranibizumab (Lucentis; Genentech). There are currently no published reports on the use of aflibercept (Eylea; Regeneron Pharmaceuticals, Inc., Tarrytown, NY) in human neonates. However, in an oxygeninduced retinopathy canine model, a study found that the dose of VEGF-trap balances the effect of regression of neovascularization against development of normal retinal vascularization, with higher doses inhibiting normal retinal vascularization. 22 Studies have also investigated the use of aflibercept in a mouse model of oxygen-induced retinopathy, and found this compound to be effective at regressing neovascularization but with increased areas of avascular retina and corresponding decreased electroretinographic amplitudes. 23 In this preclinical oxygen-induced retinopathy mouse model, intravitreal afilbercept resulted in abnormal structural changes in retinal layers despite vascular recovery, suggesting that VEGF suppression may adversely impact neuronal development. 23 VEGF-trap agents such as aflibercept remain to be extensively studied as an appropriate anti-VEGF agent in the treatment of ROP. 24 There may be several reasons why bevacizumab has been the most commonly reported agent to treat ROP. First, bevacizumab and ranibizumab provide complete blockage of VEGF-A, whereas pegaptanib provides only partial blockage of VEGF-A activity. Second, bevacizumab is a full-length 149-kDa antibody, unlike the 40-kDa antibody fragment ranibi- Figure 1 . The number of clinical studies in neonates investigating the use of intravitreal anti-vascular endothelial growth factor therapy for the treatment of retinopathy of prematurity has been rapidly increasing in recent years. All studies included in this figure are detailed in Table A (available in the online  version of this article). zumab. Given the possible long-term adverse effects of VEGF blockage in the neonate, full-length antibodies may have less tissue penetration and therefore less systemic absorption compared to antibody fragments. Even so, ranibizumab has been suggested as a better option given that additional phamacokinectic factors such as systemic half-life (ranibizumab [2 hours] versus bevacizumab [20 days]) make antibody fragments such as ranibizumab theoretically safer. 25 Preliminary studies have suggested that intravitreal ranibizumab in neonates may only suppress systemic VEGF levels for 2 to 3 weeks, 26 whereas intravitreal bevacizumab in neonates may cause systemic VEGF level suppression for up to 7 weeks after injection. 27 Domestically, as health care costs continue to climb, and internationally, where cost-conscious care is paramount, bevacizumab is a more a costeffective option compared to other more expensive anti-VEGF agents.
DOSING AND SYSTEMIC SAFETY
All anti-VEGF agents discussed in this article, including bevacizumab, as a treatment of ROP are strictly off-label at this time, with package inserts stating "the safety and effectiveness in pediatric patients has not been established." This stems from the 1962 Kefauver-Harris amendments to the Food, Drug, and Cosmetic statutes, whose goal was to ensure documented benefit to the patient in addition to safety, but has unfortunately led to exclusionary wording in the labeling of approximately 80% of drugs approved by the U.S. Food and Drug Administration (FDA) for infants and children throughout the past 30 years. 28 Ophthalmologists who treat ROP have also received precautionary warnings from the manufacturer of Avastin and Lucentis, warning of the potential safety risks of anti-VEGF agents for the treatment of ROP. However, the FDA and pharmaceutical manufacturers do not regulate the practice of medicine, including the off-label use of medications. 29 Therefore, in proper clinical situations along with the support of hospital Ethics Committees, the use of anti-angiogenic agents for the treatment of ROP has become more common and these compounds may establish themselves as an effective and accepted off-label treatment for ROP. Collaborative efforts by health care providers treating ROP, the FDA, the National Institutes of Health, and pharmaceutical companies are needed to establish the same level of safety for ocular antiangiogenic medications in children as they currently command in adults. 30 No study, including the BEAT-ROP study, has been adequately powered to evaluate the safety of these compounds in neonates. Clinicians have reported extensively on the use of intravitreal bevacizumab for the treatment of ROP, but optimal dose, proper posterior limbal injection distance, adequate follow-up interval after treatment, and re-treatment guidelines remain to be defined. Historically, the most commonly used dose of intravitreal bevacizumab for off-label use in adults with age-related macular degeneration (AMD) is 1.25 mg/0.05 mL. 31 In early case reports of ROP treated with intravitreal bevacizumab, doses as high as 1.25 mg were used, but later investigators were keen to point out that even halving the adult dose (0.625 mg/0.025 mL) in the pediatric eye would deliver a relatively large amount of drug when considering neonatal eye anatomical proportions including vitreous volume and axial length. 32, 33 There has been a trend to lower the dose of bevacizumab, with more recent reports using doses in the range of 0.375 to 1.25 mg. [34] [35] [36] Minimizing the amount of drug is an important consideration given the concern of systemic absorption and potential adverse events in young children. Concerns for systemic absorption after intravitreal injection were first noted with the early use of intravitreal bevacizumab for proliferative diabetic retinopathy, when it was observed there was reduction in leakage of neovascularization in the contralateral, un-injected fellow eye. 25, 37 Rabbits injected with intravitreal bevacizumab have shown suppression of systemic VEGF levels up to 8 days after injection. 38 Studies have shown that intravitreal bevacizumab in eyes with ROP results in systemic absorption of drug and a reduction in circulating systemic VEGF levels.
39-41 A report has also found a bilateral effect of unilateral intravitreal bevacizumab for the treatment of ROP.
42 VEGF is thought to be an important neuronal protectant under ischemic conditions 43 and particularly important for the survival of retinal neurons 44, 45 and maintenance of the retinal pigment epithelium.
46 VEGF is also involved in the development of many organ systems, including the liver, kidney, and lung. Pulmonary development is critical in neonates and pulmonary-related complications are a significant cause of morbidity and mortality in this population. In the BEAT-ROP study, although not statistically significant, there were four deaths related to lung disease in the bevacizumab arm and only one death attributable to lung disease in the laser arm, raising potential concerns regarding the effect of VEGF blockage on pulmonary maturation. 12 From large, population-based studies using anti-VEGF treatments for AMD such as the CATT trial 47 and review of Medicare claims data, 48 there are reports of associated systemic side effects of intravitreal anti-VEGF treatment including arteriothrombotic events, systemic hemorrhage, congestive heart failure, hypertension, and vascular death. A large meta-analysis has shown that intravitreal ranibizumab is associated with cerebrovascular accidents, 49 but was later refuted in a letter to the editor. 50 Systemic intravenous administration of bevacizumab has also been associated with adverse events such as sudden death, stroke, systemic hypertension, and gastrointestinal bleeding, among others. 51, 52 Furthermore, children with ROP previously treated with lasers may be at higher risk of systemic absorption given destruction of the natural full-thickness retinal barrier. Despite these reported associations and known systemic side effects, only one series observed hepatic dysfunction in a child treated with intravitreal bevacizumab; however, a definitive causative relation from the intravitreal bevacizumab therapy could not be established. 53 Although relatively few or no true systemic side effects have been reported in children treated with intravitreal anti-VEGF for ROP, follow-up time remains limited.
Proponents of anti-VEGF therapy for ROP point out that in an animal model, intravitreal delivery had minimal effect on the electrophysiology of photoreceptors and caused no significant histopathologic changes. 54 Likewise, in a pediatric ROP eye treated with intravitreal bevacizumab, there was normal retinal development and preserved cellular architecture with no adverse histopathologic features. 55 At the same time, other reports suggest an adverse effect on retinal architecture in an animal model. 23 Follow-up remains limited and samples sizes too small to evaluate the systemic safety of intravitreal anti-VEGF in the pediatric population, and use remains strictly offlabel. In addition, because premature infants may be at risk of developmental issues regardless of having an intravitreal injection of anti-VEGF therapy, in the neonatal population at risk for ROP requiring treatment, it may be challenging to determine if developmental changes are secondary to intravitreal injection of an anti-VEGF agent or are a result of inherent sequelae of prematurity. 56, 57 Local adverse events are a potential complication of all intravitreal injections. Aside from the relatively well-known "ROP crunch" side effect in eyes with ROP with pre-treatment traction that progresses to retinal detachment as a result of rapid regression of fibrovascular membranes, 58 there have been few local complications reported in the literature. One report noted possible "choroidal rupture" in an eye treated concurrently with laser and intravitreal bevacizumab, 59 which was also reported in another more recent series. 53 A study from Taiwan reported vitreous or preretinal hemorrhage in 8% of eyes (eventually resolved in all cases) and transient venous sheathing in 4% of eyes as complications of intravitreal bevacizumab injection. 60 An updated study with a larger number of eyes and longer follow-up from the Taiwanese group reported vitreous or preretinal hemorrhage (ultimately resolving in all cases), cataract (not directly related to trauma during intravitreal injection), and exotropia each occurring in 1% of all eyes. 61 A series from India reported retinal breaks and bilateral vascular attenuation with subretinal perivascular exudates and optic atrophy after adjuvant treatment with intravitreal bevacizumab. 53 Another report from India noted hypotony with exudative retinal detachment and choroidal whitening consistent with choroidal ischemia 16 hours after intravitreal injection of bevacizumab. 62 With regard to local side effects (chiefly trauma and infection), intravitreal anti-VEGF treatment for ROP has a low reported incidence of complications. This may or may not be consistent with actual clinical practice because published literature may underreport the true incidence of local complications of intravitreal injections in this patient population. Given limited follow-up, uncertainty remains regarding ocular and systemic side effects of intravitreal bevacizumab and other anti-VEGF agents.
OPTIMAL TREATMENT PARAMETERS FOR
INTRAVITREAL ANTI-VEGF The optimal therapeutic window for anti-VEGF therapy for ROP remains to be determined. Studies have shown there is a significant increase in VEGF levels in stage 4 disease, 10 indicating that the most favorable treatment time would be in less advanced ROP, before VEGF levels rapidly increase.
Unlike disease entities such as AMD and proliferative diabetic retinopathy that continually release VEGF, 63, 64 ROP follows distinct phases with a peak of VEGF promoting neovascularization. 65 Accordingly, a single, appropriately timed injection of anti-VEGF therapy may be curative. Furthermore, laser therapy can only prevent the release of further VEGF, whereas intravitreal anti-VEGF injection has the advantage of acting against already released VEGF. It is also important to note that VEGF alone is unlikely to be the only therapeutic target in ROP 66 and preclinical models continue to investigate the pathogenesis of this disease entity. 67 Optimal follow-up is also an important consideration in children who have been treated with primary intravitreal bevacizumab, with data indicating that eyes achieving successful regression with primary intravitreal anti-VEGF treatment recur at a later interval than patients who are treated with primary laser therapy. 68 Even in studies such as the BEAT-ROP trial, the mean recurrence interval for zone I disease was 6.4 ± 6.7 weeks after laser treatment but 19.2 ± 8.6 weeks after intravitreal bevacizumab, and the 54-week endpoint of the study may have been too early to observe all recurrences after intravitreal bevacizumab treatment. 69, 70 Investigators have commented, "treatment with bevacizumab is not a one-and-done therapy" 70 and the minimum follow-up period after intravitreal therapy has not been conclusively established. As follow-up time increases after primary treatment with intravitreal bevacizumab, more studies are reporting late reactivation, highlighting the need for prolonged monitoring after intravitreal bevacizumab as a treatment for ROP. 71, 72 And with the issues of delayed normal retinal vascularization, 36 potential late recurrence of disease, and abnormal vascular patterns after intravitreal anti-VEGF therapy 73 that may persist for long periods of time, 36 the need for sequential imaging and fluorescein angiography after treatment will likely become increasingly more important.
ADMINISTRATION TECHNIQUE
Intravitreal injection technique has important considerations in the neonate, given the lens is larger relative to the overall ocular volume, requiring appropriate injection distance posterior to the limbus, needle gauge, and length of needle. The posterior distance at which injections are performed varies, ranging from 1 mm (pars plicata) to 2 to 3 mm (retina) posterior to the limbus. Needle gauge is also not standardized, but 27 or 30 gauge is used most commonly. Most often, intravitreal anti-VEGF therapy typically does not require anesthesia, thereby allowing treatment of neonates too ill to undergo general anesthesia, which is often required for laser treatment. If sedation is required for intravitreal injection in a neonate, inhalation anesthesia with seveoflurane has an excellent safety profile per a recent report. 74 Additionally, intravitreal anti-VEGF may be an increasingly important treatment option for developing countries and the "third epidemic of ROP" where clinical skills and time of practicing ophthalmologists are limited.
QUALITY OF EVIDENCE OF INTRAVITREAL
ANTI-VEGF TREATMENT Confounding the debate of anti-VEGF treatment for ROP further is that much of the literature comprises only small series or case reports. These reports often are not using intravitreal anti-VEGF as a primary treatment, but more commonly concurrently with laser or as salvage therapy for eyes that have progressed despite laser treatment. Other reports comment on the preoperative use of intravitreal bevacizumab prior to vitrectomy for more advanced ROP. 75 The significant variability of reports on this therapy make it difficult to draw strong, broad-reaching conclusions. Even well-conceived trials, such as BLOCK-ROP, that set out to further investigate the safety of intravitreal bevacizumab have been terminated due to low recruitment as a result of stringent enrollment criteria. In the face of these obstacles, what is the practicing ophthalmologist treating ROP to do?
CONCLUSION
The increasing use of anti-VEGF treatment for ROP represents an important paradigm shift and crossroads for the treatment of this pediatric vitreoretinal disease. For the past 7 years, it has been clear that anti-VEGF therapy for ROP promotes regression of disease. We have also learned that imaging and fluorescein angiography may play a critical role in the treatment of these patients, given the possibility of prolonged peripheral ischemia and abnormal vascular patterns that may occur after anti-VEGF treatment for ROP. However, the same questions remain regarding timing, dosage, and adverse events when using anti-VEGF agents for ROP. Future stud-ies will continue to add to our growing knowledge regarding the risks and benefits of anti-VEGF therapy for ROP. Ideally, studies should seek to achieve the highest therapeutic effect of anti-VEGF agents with the lowest effective dose to minimize potential systemic adverse events. Until more is known, it is prudent to not be tempted by short-term gains in the face of unknown long-term effects. Likewise, for a proper subset of eyes at high risk of failure or not amenable to laser treatment (eg, poor mydriasis, opacified media, posterior zone 1 disease, and failure of laser therapy), the extensive and growing body of literature on anti-VEGF treatment for ROP provides an encouraging foundation to consider this therapy. Literature search of PubMed using terms retinopathy of prematurity, ROP, anti-VEGF, Avastin®, bevacizumab, Lucentis®, ranibizumab, Macugen®, pegaptanib identified potential studies to be included. Then, author review of all available literature based on search terms included only clinical human studies involving anti-VEGF blockage as a primary, adjuvant or salvage therapy for ROP and whose primary endpoints were to report the outcomes with anti-VEGF therapy as a treatment for ROP. One study in this table (reference #117) is an oral presentation from a research conference (not indexed on PubMed), but is included given the limited literature on pegaptanib (Macugen®) as a treatment for ROP. Articles not translated into English were excluded. 
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